高级检索

日本罕用药制度及其对中国的启示——基于对日本罕用药可及性的评价

丁志琛, 韦冠, 丁锦希

丁志琛, 韦冠, 丁锦希. 日本罕用药制度及其对中国的启示——基于对日本罕用药可及性的评价[J]. 中国药科大学学报, 2014, 45(1): 118-124. DOI: 10.11665/j.issn.1000-5048.20140122
引用本文: 丁志琛, 韦冠, 丁锦希. 日本罕用药制度及其对中国的启示——基于对日本罕用药可及性的评价[J]. 中国药科大学学报, 2014, 45(1): 118-124. DOI: 10.11665/j.issn.1000-5048.20140122
shu
DING Zhichen, WEI Guan, DING Jinxi. Orphan drug regime in Japan and enlightenment on China:based on evaluation of orphan drug access in Japan[J]. Journal of China Pharmaceutical University, 2014, 45(1): 118-124. DOI: 10.11665/j.issn.1000-5048.20140122
Citation: DING Zhichen, WEI Guan, DING Jinxi. Orphan drug regime in Japan and enlightenment on China:based on evaluation of orphan drug access in Japan[J]. Journal of China Pharmaceutical University, 2014, 45(1): 118-124. DOI: 10.11665/j.issn.1000-5048.20140122
shu

日本罕用药制度及其对中国的启示——基于对日本罕用药可及性的评价

  • 中国药科大学国际医药商学院

基金项目: 国家社会科学基金资助项目(No.13BFX120)

Orphan drug regime in Japan and enlightenment on China:based on evaluation of orphan drug access in Japan

摘要

    摘要
  • 摘要: 以日本罕用药制度为参考蓝本，在系统解析日本罕用药制度的基础上，从审批前资格认证、审批上市过程以及上市后监管等方面剖析日本罕用药制度，并对其进行评价。研究表明，日本较为完备的一套罕用药制度收效甚好，有效地促进了罕用药的研发及其可及性的提高，由此为我国罕用药制度的构建提供借鉴意义和理论依据。
    Abstract: With Japan as the target for reference and on the basis of systematic analysis of orphan drug regime in Japan, this paper analyzed orphan drug regime in Japan from the aspects of pre-approval designation, approving and marketing phase and post-marketing administration, and also provided the corresponding operating performance evaluation. The study results indicated that the mature orphan drug system in Japan has yielded good effects in that it has effectively facilitated orphan drug R&D and improved the access, thereby providing referable and valuable theoretical foundation for the construction of orphan drug regime in China.
    • HTML全文
    • 参考文献(20)
  • [1] Ding JX,Luo XW,Wang YW.Evaluation of Japanese data protection system from the perspective of economics—the empirical analysis based on the performance of reexamination policy on Japanese innovative drugs[J]. Shanghai Med Pharm J(上海医药),2011.32(12):615-620.
    [2] 唐闻佳.“孤儿药”谁来“抱”? 罕见病患者看到未来曙光[EB/OL].(2012-03-02)http://sh.eastday.com/m/20120302/u1a6397098.html
    [3] Minghetti PM,Giudici EM,Montanari L.A proposal to improve the supply of orphan drugs[J].Pharmacol Res,2000,42(1):33-37.
    [4] Uchida K.Orphan drugs in Japan[J]. Drug Inf J,1996,30(1):171-175.
    [5] Tao Y,Bu YF,Zhang C,et al.Orphan drug management systems in Japan(日本的罕用药管理制度)[J]. Chin Pharm J(中国药学杂志),2002,37(6):468-470.
    [6] Shah RR.Chapter 11 Regulatory framework for the treatment of orphan diseases[EB/OL].http://www.ncbi.nlm.nih.gov/books/NBK11567/.
    [7] Scott DL,Alder S,Usui E,et al.Orphan drug programs/policies in Australia,Japan,and Canada[J].Drug Inf J,2001,35(1):11-13.
    [8] Gong SW. Management strategies of improving orphan drugs accessibility in China(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and technology,2008.
    [9] Yang L,Chen YW,Huang Z,et al.Research on the orphan drug exclusivity system[J].Chin Pharm Aff(中国药事),2010,24(1):49-52.
    [10] Villa S,Compagni A,Reich MR.Orphan drug legislation:lessons for neglected tropical diseases[J].Int J Health Plann Manage,2009, 24(1):27-42.
    [11] Zhang KJ.Interpretation and reflection on fast tract review in drug registration in developed countries[J].China Prescr Drug(中国处方药),2009,(90):66-67.
    [12] Pharmaceuticals and Medical Devices Agency. Profile of services 2013-2014[EB/OL].[2013-12-20]. http://www.pmda.go.jp/english/about/pdf/profile_of_services.pdf.
    [13] MSF.Data exclusivity in international trade agreements:What consequences for access to medicines[EB/OL]?[2013-12-20]http://www.citizen.org/documents/DataExclusivityMay04.pdf.
    [14] Guo Y,Zhang HL,Chen J,et al.Drug price policies in Japan and its enlightenment to China(日本药品价格政策研究及对我国的启示)[J].China J Pharm Econ(中国药物经济学),2010(4):63-67.
    [15] Tao Y,Shao YF,Zhang C,et al.History and current status of orphan drug administration in the U.S.(美国罕用药管理的历史与现状)[J]. Chin Pharm J(中国药学杂志),2001,36(9):634-636.
    [16] Guan XD,Shi LW.Establishment of national essential drug policies(建立我国国家基本药物政策的研究)[J]. Chin Pharm J(中国药学杂志),2009,44(2):158-160.
    [17] Li HT.Discussing the drug′s accessibility in China[J].Chin Health Serv Manage(中国卫生事业管理),2009,26(9):612-614.
    [18] Feng JH.The crises of public health,access to pharmaceuticals and its parallel import[J].J Law Appl(法律适用),2004,(12):15-18.
    [19] Ding JX,Zhao M.The comparative study on supervision and incentive policies of Sino-US during the innovative drug R&D[J].China J New Drug(中国新药杂志),2009,18(5):387-392.
    [20] Wu SY,Zhang K.Establishment of rare disease research and preventive strategies(关于建立罕见病研究和防治策略的思考)[J].Chin Health Resour(中国卫生资源),2011,14(5):317-319.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  2170
  • HTML全文浏览量:  4
  • PDF下载量:  1953
  • 被引次数: 0
出版历程
  • 刊出日期:  2014-02-24

目录

摘要
HTML全文
    参考文献(20)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：457711

    x 关闭 永久关闭

    《中国药科大学学报》对钓鱼邮件的严正声明！